Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice (original) (raw)

• Jones, S. et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321, 1801–1806 (2008).
  Article CAS Google Scholar
• Sharpless, N.E. & Depinho, R.A. The mighty mouse: genetically engineered mouse models in cancer drug development. Nat. Rev. Drug Discov. 5, 741–754 (2006).
  Article CAS Google Scholar
• Frese, K.K. & Tuveson, D.A. Maximizing mouse cancer models. Nat. Rev. Cancer 7, 645–658 (2007).
  Article CAS Google Scholar
• Olive, K.P. & Tuveson, D.A. The use of targeted mouse models for preclinical testing of novel cancer therapeutics. Clin. Cancer Res. 12, 5277–5287 (2006).
  Article CAS Google Scholar
• Rangarajan, A. & Weinberg, R.A. Opinion: comparative biology of mouse versus human cells: modelling human cancer in mice. Nat. Rev. Cancer 3, 952–959 (2003).
  Article CAS Google Scholar
• Fu, X., Guadagni, F. & Hoffman, R.M. A metastatic nude-mouse model of human pancreatic cancer constructed orthotopically with histologically intact patient specimens. Proc. Natl. Acad. Sci. USA 89, 5645–5649 (1992).
  Article CAS Google Scholar
• Loukopoulos, P. et al. Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity. Pancreas 29, 193–203 (2004).
  Article CAS Google Scholar
• Rubio-Viqueira, B. et al. An in vivo platform for translational drug development in pancreatic cancer. Clin. Cancer Res. 12, 4652–4661 (2006).
  Article CAS Google Scholar
• Rubio-Viqueira, B. & Hidalgo, M. Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients. Clin. Pharmacol. Ther. 85, 217–221 (2009).
  Article CAS Google Scholar
• Flanagan, S.P. 'Nude', a new hairless gene with pleiotropic effects in the mouse. Genet. Res. 8, 295–309 (1966).
  Article CAS Google Scholar
• Trevino, J.G. et al. Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am. J. Pathol. 168, 962–972 (2006).
  Article CAS Google Scholar
• Gray, M.J. et al. Neuropilin-1 suppresses tumorigenic properties in a human pancreatic adenocarcinoma cell line lacking neuropilin-1 coreceptors. Cancer Res. 65, 3664–3670 (2005).
  Article CAS Google Scholar
• Bosma, G.C., Custer, R.P. & Bosma, M.J. A severe combined immunodeficiency mutation in the mouse. Nature 301, 527–530 (1983).
  Article CAS Google Scholar
• Ito, M. et al. NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood 100, 3175–3182 (2002).
  Article CAS Google Scholar
• Quintana, E. et al. Efficient tumour formation by single human melanoma cells. Nature 456, 593–598 (2008).
  Article CAS Google Scholar
• Voskoglou-Nomikos, T., Pater, J.L. & Seymour, L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin. Cancer Res. 9, 4227–4239 (2003).
  Google Scholar
• Johnson, J.I. et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br. J. Cancer 84, 1424–1431 (2001).
  Article CAS Google Scholar
• End, D.W. et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro . Cancer Res. 61, 131–137 (2001).
  CAS Google Scholar
• Van Cutsem, E. et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J. Clin. Oncol. 22, 1430–1438 (2004).
  Article CAS Google Scholar
• Garber, K. From human to mouse and back: 'tumorgraft' models surge in popularity. J. Natl. Cancer Inst. 101, 6–8 (2009).
  Article Google Scholar
• Fichtner, I. et al. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin. Cancer Res. 14, 6456–6468 (2008).
  Article CAS Google Scholar
• Houghton, P.J. et al. The pediatric preclinical testing program: description of models and early testing results. Pediatr. Blood Cancer 49, 928–940 (2007).
  Article Google Scholar
• Peterson, J.K. & Houghton, P.J. Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. Eur. J. Cancer 40, 837–844 (2004).
  Article CAS Google Scholar
• Hoffman, R.M. Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest. New Drugs 17, 343–359 (1999).
  Article CAS Google Scholar
• Li, C. et al. Identification of pancreatic cancer stem cells. Cancer Res. 67, 1030–1037 (2007).
  Article CAS Google Scholar
• Al-Hajj, M., Wicha, M.S., Benito-Hernandez, A., Morrison, S.J. & Clarke, M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 100, 3983–3988 (2003).
  Article CAS Google Scholar
• O'Brien, C.A., Pollett, A., Gallinger, S. & Dick, J.E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445, 106–110 (2007).
  Article CAS Google Scholar
• Kim, M.P., Gallick, G.E., Evans, D.B., Wang, H.M. & Fleming, J.B. Effect of preoperative therapy on engraftment of pancreatic adenocarcinoma tumor in mice after pancreatectomy. Proceedings of the 2009 American Society of Clinical Oncology—Gastrointestinal Cancers Symposium, 15–17 January 2009, San Francisco, CA. Abstract no. 165, p 142.
• Kim, M.P., Fleming, J.B., Evans, D.B., Wang, H.M. & Gallick, G.E. Pancreatic cancer xenografts contain distinct populations of cells expressing the cancer stem cell marker CD133. Proceedings of the 2009 American Society of Clinical Oncology—Gastrointestinal Cancers Symposium, 15–17 January 2009, San Francisco, CA. Abstract no. 150, p 135.
• Bruns, C.J., Harbison, M.T., Kuniyasu, H., Eue, I. & Fidler, I.J. In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice. Neoplasia 1, 50–62 (1999).
  Article CAS Google Scholar
• Khanbolooki, S. et al. Nuclear factor-kappaB maintains TRAIL resistance inhuman pancreatic cancer cells. Mol. Cancer Ther. 5, 2251–2260 (2006).
  Article CAS Google Scholar
• Nawrocki, S.T., Sweeney-Gotsch, B., Takamori, R. & McConkey, D.J. The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts. Mol. Cancer Ther. 3, 59–70 (2004).
  CAS PubMed Google Scholar